Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sudhir Kumar has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Mechanisms Driving Metastatic Progression Within the Aged Tumor Microenvironment

    by Sudhir Kumar, Jagdish Chand, Preeti Sharma, Sudhakar Singh, Pukar Khanal, Hanish Singh Jayasingh Chellammal, Aamir Suhail, Sonam Mittal

    Metastasis remains the leading cause of cancer deaths, heavily influenced by aging-related biological processes. As global life expectancy increases, cancer incidence and progression complexity in older adults also rise, emphasizing the urgent need to understand how the aging tumor microenvironment (TME) promotes metastasis. This review explores the molecular and cellular mechanisms behind metastatic development in the aged TME, focusing on the combined impacts of cellular senescence, chronic inflammation (inflammaging), immune system decline, extracellular matrix (ECM) changes, and abnormal blood vessel growth. Aging causes an accumulation of senescent cells that secrete a range of cytokines, growth factors, and enzymes (SASPs), which remodel the ECM, making it stiffer and more degradable, and activate pro-metastatic pathways like TGF-β, STAT3, and MAPK, aiding processes like EMT and tumor invasion. Meanwhile, persistent low-grade inflammation attracts immunosuppressive cells, and immune decline hampers tumor surveillance, allowing cancer cells to evade immune detection. The aged TME also undergoes significant vascular and metabolic changes, such as abnormal angiogenesis and hypoxia, supporting the growth of more aggressive, treatment-resistant cancer clones and spreading metastases. These changes are driven by hallmarks of molecular aging, including telomere shortening, oxidative DNA damage, and epigenetic alterations, which lead to genetic instability and turn the aged stroma into fertile ground for metastasis. The review also discusses new therapeutic approaches, including senolytics, anti-inflammatory treatments, immune system rejuvenation, and metabolic strategies, highlighting the importance of age-specific models and precision medicine to enhance outcomes for the growing number of elderly cancer patients.


  • Advanced Delivery Systems and Gene Editing in Neurotherapeutics

    by Prabhat Upadhyay, Aamir Suhail, Sudhir Kumar

  • Lifestyle, Diet, and the Gut–Brain Axis in Neuroprotection

    by Preeti Sharma, Neha Verma, Anushka Verma, Ankita Wal, Sudhir Kumar, Prabhat Upadhyay

  • Open Access

    Mechanistic insights and biomarker discovery in immune cell aging and age-associated diseases

    by Prabhat Upadhyay, Aamir Suhail, Pukar Khanal, Sudhir Kumar

    Immunosenescence is the progressive deterioration of immune function with aging and is driven by dynamic molecular and cellular interactions, most notably the chronic low-grade inflammation (inflammaging). This inflammatory state arises from lifelong antigen exposure, environmental stress, and hormonal shifts, culminating in paradoxical immune dysfunction: innate immune cells exhibit numerical expansion but functional decline, including impaired macrophage phagocytosis and diminished dendritic cell-mediated T cell priming. Advances in single-cell RNA sequencing have uncovered biomarkers of immune aging, such as upregulation of cyclin-dependent kinase inhibitors (CDKN1A/p21 and CDKN2A/p16INK4a) and senescence-associated secretory phenotype (SASP) components like IL-6, IL-8, and TNF-α. Concurrent epigenetic dysregulation, such as EZH2-dependent H3K27me3 alterations and global DNA methylation shifts, further orchestrates immune decline. The adaptive immune system undergoes profound remodeling, marked by thymic involution, skewed T cell receptor diversity, and B cell repertoire contraction, which collectively impair responses to novel antigens and vaccination efficacy. Elucidating these mechanisms provides a roadmap for targeting strategies to restore immune resilience in aging populations.


  • Open Access

    Epigenetic modulation of BARD1 to enhance anti-VEGF therapy

    by Emine Bayraktar, Cristian Rodriguez-Aguayo, Elaine Stur, Sudhir Kumar, Lingegowda S. Mangala, Nicholas B. Jennings, Nazende Nur Bayram, Sara Corvigno, Amma Asare, Cristina Ivan, et al.


  • Top Cited Papers
    Open Access

    Dual role of lactate in human health and disease

    by Sudhir Kumar, Neha Sahu, Talha Jawaid, Hanish Singh Jayasingh Chellammal, Prabhat Upadhyay

    Lactate, traditionally seen as a byproduct of anaerobic metabolism, has gained attention for its dual role in human health. While it is associated with muscle fatigue, lactate also plays a crucial role in various physiological and pathological processes. This review explores lactate’s dual nature as both beneficial and detrimental. Under normal physiological conditions, lactate is an essential energy substrate, involved in the Cori cycle, where it is converted back to glucose in the liver. However, excessive lactate accumulation is linked to health issues, including cancer, metabolic disorders, and neurological diseases. The Warburg effect in cancer, characterized by increased lactate production even in oxygen-rich environments, promotes tumor progression and therapy resistance. In diseases like malaria and ischemic stroke, high lactate levels contribute to tissue damage and metabolic disturbances. Recent research also highlights lactate’s beneficial roles, including regulation of immune responses, enhanced exercise performance, and neuronal signaling. Furthermore, gut microbiota significantly impacts lactate metabolism, where beneficial bacteria use lactate to maintain gut health, while some pathogenic bacteria exacerbate disease through excess lactate production. Emerging therapeutic potential of lactate, including lactate dehydrogenase inhibitors, offers promising treatment avenues. This review provides a comprehensive overview of lactate’s complex role in health and disease, emphasizing the need for targeted strategies to harness its benefits while mitigating its harmful effects.


  • Open Access

    Gut Microbiome rewiring via fecal transplants: Uncovering therapeutic avenues in Alzheimer’s disease models

    by Prabhat Upadhyay, Sudhir Kumar, Anurag Tyagi, Aayush Raj Tyagi, Tarun Barbhuyan, Sarika Gupta

    Emerging evidence implicates the gut microbiome in Alzheimer’s disease (AD) pathogenesis, yet the underlying mechanisms remain elusive. This study elucidates the bidirectional relationship between gut microbiota and AD using fecal microbiota transplantation (FMT) in a mouse model. Through meticulous experimentation, we conducted reciprocal FMT between AD (5xFAD) and healthy (C57BL/6) mice to unravel the impact of gut microbiome alterations on cognitive function and neuroinflammation. FMT from 5xFAD to C57BL/6 mice induced profound memory impairment and cognitive deficits, accompanied by elevated inflammatory cytokine levels, oxidative stress markers, and systemic inflammation, as evidenced by increased plasma cytokines. Conversely, transplanting healthy microbiota into 5xFAD mice yielded remarkable behavioral improvements, including enhanced spatial memory performance in the Morris water maze, directly correlating with cognitive recovery. Our findings underscore the pivotal role of the gut microbiome in AD pathogenesis and offer a promising therapeutic avenue. Targeted modulation of the gut microbiome through strategies like FMT may offer potential benefits in Alzheimer’s disease by influencing neuroinflammation, oxidative stress, and cognitive function. This comprehensive study provides novel insights into the gut-brain axis dynamics and paves the way for innovative microbiome-based interventions in AD management.


  • Top Cited Papers

    Diabetes and Bone Health: A Comprehensive Review of Impacts and Mechanisms

    by Prabhat Upadhyay, Sudhir Kumar

    Diabetic bone disease, a form of secondary osteoporosis, is characterised by reduced bone strength and increased fracture risk, particularly in patients with type 2 diabetes (T2D). Over 35% of T2D patients experience bone loss, with approximately 20% meeting diagnostic criteria for osteoporosis. This review highlights the complex mechanisms underlying diabetic bone disease, emphasising the need to reduce fracture risk and improve clinical outcomes. Key factors such as hyperglycemia, insulin resistance, insulin‐like growth factors (IGFs), advanced glycation end products (AGEs), and proinflammatory cytokines disrupt bone turnover by impairing osteoblast and osteoclast function, leading to imbalanced bone formation and resorption. We explore the role of bone turnover and mineralisation in both cortical and trabecular bone, and the impact of microvascular complications on bone microarchitecture. Gut hormones, including Glucagon‐like peptide‐1 (GLP‐1), Glucose‐dependent insulinotropic polypeptide (GIP), and Parathyroid hormone (PTH), and the gut microbiota also play crucial roles in the pathogenesis of diabetic bone disease. Specific bacterial species, such as Akkermansia muciniphila and Bacteroides fragilis , are implicated in modulating the gut‐bone axis through short‐chain fatty acids (SCFAs) and other signalling pathways. These changes, along with altered gut hormone responses, affect bone density, microstructure, and material properties. Despite normal or increased bone mineral density (BMD) in some T2D patients, the material quality of bone is compromised, leading to greater fragility. This review integrates current knowledge of molecular, hormonal, and microbial interactions that contribute to diabetic bone disease, offering insights into potential therapeutic strategies and improving patient care.


  • Open Access

    Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer

    by Anjali Geethadevi, Zhiqiang Ku, Shirng-Wern Tsaih, Deepak Parashar, Ishaque P. Kadamberi, Wei Xiong, Hui Deng, Jasmine George, Sudhir Kumar, Sonam Mittal, et al.

    Chemotherapy such as cisplatin is widely used to treat ovarian cancer either before or after surgical debulking. However, cancer relapse due to chemotherapy resistance is a major challenge in the treatment of ovarian cancer. The underlying mechanisms related to chemotherapy resistance remain largely unclear. Therefore, identification of effective therapeutic strategies is urgently needed to overcome therapy resistance. Transcriptome-based analysis, in vitro studies and functional assays identified that cisplatin-resistant ovarian cancer cells express high levels of OSMR compared to cisplatin sensitive cells. Furthermore, OSMR expression associated with a module of integrin family genes and predominantly linked with integrin αV (ITGAV) and integrin β3 (ITGB3) for cisplatin resistance. Using ectopic expression and knockdown approaches, we proved that OSMR directly regulates ITGAV and ITGB3 gene expression through STAT3 activation. Notably, targeting OSMR using anti-OSMR human antibody inhibited the growth and metastasis of ovarian cancer cells and sensitized cisplatin treatment. Taken together, our results underscore the pivotal role of OSMR as a requirement for cisplatin resistance in ovarian cancer. Notably, OSMR fostered the expression of a distinct set of integrin genes, which in turn resulted into a crosstalk between OSMR and integrins for signaling activation that is critical for cisplatin resistance. Therefore, targeting OSMR emerges as a promising and viable strategy to reverse cisplatin-resistance in ovarian cancer.


  • Open Access

    Protocol for the isolation of tumor cell-derived extracellular vesicles followed by in vivo metastasis assessment in a murine ovarian cancer model

    by Sonam Mittal, Sudhir Kumar, Prachi Gupta, Mona Singh, Pradeep Chaluvally-Raghavan, Sunila Pradeep